 It works by targeting amyloid in the brain, which is considered to be a hallmark of the disease. It will be sold under the brand name Kisaluna and is the second approved Alzheimer's drug of its kind. Now, the president of the Alzheimer's Association says this is real progress. This allows and this approval allows people more options and greater opportunity to have more time.